VR contact lens video developed for the waiting room

Eye Fatigue

A virtual reality contact lens video has been developed as an educational tool to be used by patients in the waiting room.

Global communications agency Five by Five developed a 360-degree virtual reality (VR) video on behalf of contact lens manufacturer CooperVision. The video supports the launch of CooperVision’s new Bioinfinity Energys contact lens.

The video is intended to transform eye care practitioners waiting rooms into an educational experience. Customers using the tool can be informed about digital eye fatigue alongside the product benefits before their eye test. The VR video can be used with or without a headset and places viewers inside the Biofinity Energys lab. Viewers a taken through the lab by a virtual robot and come across information points containing pictures, graphics and text highlighting the product benefits.

CooperVision’s Bioinfinity Energys is a contact lens designed specifically for a digital lifestyle. The lens helps combat eye tiredness and dryness associated with digital device use.

 Paul Archer, Art director at Five by Five, said: “As this was the first time CooperVision had ventured into VR, we wanted to create a modern and playful way of educating audiences about the symptoms of digital eye fatigue and show how Biofinity Energys can address these. By using a futuristic environment, we designed the VR world to reflect the advanced technology and years of research that have gone into creating this next-generation lens.”

Rob Healey, head of Brand, Europe, for CooperVision added: “Five by Five has done a fantastic job in creating a truly engaging way of presenting eye care practitioners and consumers with the facts around digital eye fatigue and the product benefits of Biofinity Energys. The VR video is the perfect way to communicate with our audience and we can’t wait for people to take a step into the future and have a look around our new ‘lab’.”

 



'VR contact lens video developed for the waiting room' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

© 2017 Rapid Life Sciences Ltd, a Rapid News Communications Group Company. All Rights Reserved.

Privacy policy

Terms and conditions